Kamada Ltd. Reports Record 2024 Financial Results

Kamada Ltd ( (KMDA) ) has released its Q4 earnings. Here is a breakdown of the information Kamada Ltd presented to its investors.

Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies for rare and serious conditions. The company is recognized for its innovative approach in the biopharmaceutical industry, with a focus on profitable growth through strategic initiatives.

Kamada Ltd. recently announced record financial results for the year 2024, highlighting a significant increase in both revenue and profitability. The company reported total revenues of $161 million, marking a 13% increase from the previous year, and an adjusted EBITDA of $34.1 million, up 42% year-over-year. In light of these strong financial results, Kamada declared a special cash dividend of $0.20 per share, the first since its establishment.

Key financial metrics for 2024 include a net income of $14.5 million, a 75% increase compared to the prior year, and a strong cash position with $78.4 million in cash and cash equivalents. The company’s growth was driven by its diverse portfolio of FDA-approved products and strategic expansion in plasma collection operations. Kamada also secured a contract for supplying KAMRAB and V ARIZIG in Latin America, expected to generate approximately $25 million in revenue over three years.

Looking ahead, Kamada reaffirms its 2025 guidance, projecting revenues between $178 million and $182 million and an adjusted EBITDA of $38 million to $42 million. The company plans to continue its growth trajectory by focusing on organic commercial growth, strategic acquisitions, and advancing its clinical trials, particularly the pivotal Phase 3 trial for its Inhaled AAT product.

Kamada’s management remains confident in the company’s business prospects and is committed to generating shareholder value through its strategic growth pillars. The company’s strong financial position and continued investment in its product portfolio position it well for sustained growth in the coming years.